Key points are not available for this paper at this time.
EML4-ALK is found in the minority of NSCLC. ALK kinase inhibitors alone or in combination may nevertheless be clinically effective treatments for NSCLC patients whose tumors contain EML4-ALK.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jussi Koivunen
Craig H. Mermel
Kreshnik Zejnullahu
Clinical Cancer Research
Harvard University
Massachusetts Institute of Technology
Brigham and Women's Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Koivunen et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69dcc30ed4d0de07d11339c8 — DOI: https://doi.org/10.1158/1078-0432.ccr-08-0168